Member Info for RTP007

@CDF1 half of half a penny i will be very happy , but off course if anymore then great

@Scamhunter yes AB needs to get out a new positive RNS that they have booked the rig & helicoptor to assure investors, and not just reply on getting the new licence as that is not much use without investment or rig booked !!!!!!!!!!!!!

Sure you know yes great got a licence and valid till 2028 , but its worthless if have no funding or partners to move it forward , so still hanging on a string

Yes and the SP will rise like a rocket @Dulyred

Ok thanks for your comment

@Meadow1948 ,,, so as i said SP would fall back to 0.028 then rise again ,, and you said charts nothing to do with it !! strange it did what i thought

I just buy 12m and it shows as sell order

@ian12 this looks like a tit bit of seeds for investors i noted the licence expires in 2028 so sunda can drag out all other needed , as the only way things really move on this is a RNS with drill date , rig booked and helicopter, yes the licence is a step in the right direction but !!!!!

Wonder how they got on here or will they keep it a secret !!!

Oxford, UK - 3 March 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces a presentation by its Chief Data Officer Dr Ewan Hunter in the AI and Data Sciences Showcase at Precision Medicine World Conference (PMWC) 2026 in Silicon Valley.

This report I was looking at was completed by Allenby-Capital-Sunda-Energy- of which maybe many of you have already seen this

Our valuation for Sunda’s interest in SC-80 is US$56.5m or £42.0m. Using fully diluted shares of 29.93bn the latter translates into 0.14p/share.

Including Chuditch the corporate valuation for Sunda is now US$347m or £257m, equivalent to 0.86p/share.

There is clearly a substantial variance between our corporate valuation and the market capitalisation of £6.9m. This reflects, in particular, a high level of perceived uncertainty surrounding financing for the Chuditch 2 appraisal well.

Inevitably uncertainty also surrounds drilling results, although the well is considered by Sunda to be very low-risk by industry standards given the earlier discovery on the prospect and the availability of high-fidelity 3-D imaging which provides prospect definition.

We believe that once remaining logistical issues related to helicopter availability are resolved that there could be scope for a rerating of the stock.

It should be noted that resolution of helicopter availability will enable a rig to be secured and should assist in obtaining in joint-venture financing. Sunda remains confident that the Chuditch-2 well can be drilled by mid-2026.

Decision from wes streeting is due 26th march whether NHS will do anything

I think no news until end of March

Seems only get a RNS when the begging bowl for money comes out which was last october , nothing since we will be into march next and should have been updated by the end of quarter 4 2025, so quarter two 2026 nearly here

@NewuncIe I think its beteer we wait and see what Wes Streeting has to say by the end of march about whether the UK will have a screening process put in place and what compnay he might use , consultation finished on 20th Feb he now needs to review it, so lets see how it turns out

@agakhan Oxford BioDynamics (OBD) is participating in a 5-year, NCI-sponsored U.S. clinical trial (NCT05588128) using its EpiSwitch® Prostate Screening (PSE) blood test to monitor patients with biochemically recurrent prostate cancer. This 94% accurate, 3D genomic test helps monitor disease progression through regular blood collection and PSMA PET scans.

@agakhan Oxford BioDynamics (OBD) is currently focused on the commercialization and clinical application of its EpiSwitch blood-based tests in the USA, supported by a Maryland commercial office and CLIA-certified labs. Key active initiatives include the EpiSwitch Prostate Screening Evaluation (PSE) test and the EpiSwitch CiRT (Checkpoint Inhibitor Response Test).

Share Talk

Share Talk

+4

Key Current Trials and Tests in the USA (as of early 2026):

EpiSwitch CiRT (Checkpoint Inhibitor Response Test): This test is currently on the market in the US, with interim results from the ongoing PROWES trial (as of Sept 2025) demonstrating significant impact on treatment decisions for cancer patients.

EpiSwitch PSE (Prostate Screening Evaluation): Launched in the US, this test provides a 94% accuracy rate for detecting prostate cancer, showing high clinical utility compared to traditional tests.

3D Genomics Platform Expansion: OBD is partnering with Google Cloud to accelerate the deployment of their AI-powered 3D genomics platform, enhancing their diagnostic capabilities in the US market.

Oxford BioDynamics PLC

Oxford BioDynamics PLC

+5

The company is actively working on expanding the adoption of these tests and applying for inclusion in US National Comprehensive Cancer Network guidelines.

@Odins well this is not a small amount 25-Feb-26 09:50:38 0.03 121,718,176 Unknown* 0.03 0.033 36.52k but states unknown whether buy or sell order

@Slacker246 Stymied

@Slacker246 Oh Dear !! well my point DD [ debbie downer ] is that it seems you are a very unhappy individual that does not like positive and hopefully helpful in formation , and if you are invested in this stock then I suggest you ingest some positive thoughts rather then negative ones. HAND :-)

@Slacker246 & @SherlockBarty Interaction with Wes Streeting: Prostate Cancer UK and others are calling on Health Secretary Wes Streeting to update NHS guidelines to allow GPs to start proactive conversations with high-risk men, based on the findings from specialists like Oxford BioDynamics.